Important New Trial With Oral FERACCRU® Shows Comparable Efficacy to IV Iron (Ferric Carboxymaltose), Offering a Real Alternative to Hospital Administration for Many Patients[4]
Amsterdam (ots/PRNewswire) - - FERACCRU® (Ferric Maltol) met primary endpoint against Ferinject® (IV Ferric Carboxymaltose (FCM)) and shows clear benefits to Iron Deficiency Anaemia (IDA) patients with inactive Inflammatory Bowel Disease (IBD)4 - FERACCRU® delivered a haemoglobin (Hb) response rate at 12 weeks ...